Jefferies Financial Group Inc. acquired a new stake in Beta Bionics, Inc. (NASDAQ:BBNX – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 90,015 shares of the company’s stock, valued at approximately $1,708,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Perceptive Advisors LLC raised its position in shares of Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Beta Bionics during the second quarter valued at $52,340,000. Bank of New York Mellon Corp bought a new position in Beta Bionics in the second quarter valued at about $1,926,000. Squarepoint Ops LLC bought a new position in Beta Bionics in the second quarter valued at about $2,524,000. Finally, Bruce & Co. Inc. bought a new position in Beta Bionics in the first quarter valued at about $5,518,000.
Insiders Place Their Bets
In related news, CFO Stephen Feider sold 6,675 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the transaction, the chief financial officer owned 159,378 shares of the company’s stock, valued at $3,045,713.58. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 30,779 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the transaction, the insider owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. This represents a 35.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 103,069 shares of company stock worth $2,014,358 over the last ninety days. Company insiders own 5.30% of the company’s stock.
Wall Street Analyst Weigh In
BBNX has been the subject of several recent research reports. Robert W. Baird boosted their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. UBS Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a research note on Tuesday, September 15th. Piper Sandler reiterated an “overweight” rating and set a $24.00 price target (up from $20.00) on shares of Beta Bionics in a research report on Wednesday, October 28th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “strong sell” rating in a report on Saturday, October 31st. Finally, Truist Financial increased their price objective on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.69.
View Our Latest Report on Beta Bionics
Beta Bionics Stock Performance
NASDAQ BBNX opened at $16.42 on Monday. The stock has a 50-day simple moving average of $18.47 and a 200 day simple moving average of $14.86. The company has a market capitalization of $892.71 million, a PE ratio of -8.92 and a beta of 3.44. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. The firm had revenue of $35.51 million for the quarter. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. As a group, sell-side analysts predict that Beta Bionics, Inc. will post -2.04 earnings per share for the current fiscal year.
Beta Bionics Profile
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
See Also
- Five stocks we like better than Beta Bionics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX – Free Report).
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
